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Abstract
Background: Exhaled breath condensate (EBC) sampling has been considered an inventive and novel method for
the isolation of respiratory viruses.
Methods: In our study, 102 volunteers experiencing upper airway infection were recruited over the winter and
early spring of 2008/2009 and the first half of the winter of 2009/2010. Ninety-nine EBCs were successfully obtained
and screened for 14 commonly circulating respiratory viruses. To investigate the efficiency of virus isolation from
EBC, a nasal swab was taken in parallel from a subset of volunteers. The combined use of the ECoVent device with
the RTube™ allowed the registration of the exhaled volume and breathing frequency during collection. In this
way, the number of exhaled viral particles per liter air or per minute can theoretically be estimated.
Results: Viral screening resulted in the detection of 4 different viruses in EBC and/or nasal swabs: Rhinovirus,
Human Respiratory Syncytial Virus B, Influenza A and Influenza B. Rhinovirus was detected in 6 EBCs and 1 EBC was
Influenza B positive. We report a viral detection rate of 7% for the EBCs, which is much lower than the detection
rate of 46.8% observed using nasal swabs.
Conclusion: Although very promising, EBC collection using the RTube™ is not reliable for diagnosis of respiratory
infections.
Background
Human respiratory tract infections represent the most
commonly encountered infections worldwide. In the
majority of cases, the etiology of these infections
remains undetermined due to rapid convalescence after
infection. Respiratory tract infections in healthy adults
c a nb ec a u s e db yav a r i e t yo fp a t h o g e n sa n dt h ed e t e c -
tion of these agents is currently based on their isolation
from nasal swabs (NS), bronchoalveolar lavages (BAL),
nasopharyngeal aspirates and sputum samples. The
acquisition of these specimens by semi-invasive and
invasive techniques is often unpleasant for the patient.
Therefore, exhaled breath condensate (EBC) analysis has
recently been explored as a new and non-invasive
method to monitor lung inflammation and pulmonary
disease such as chronic obstructive pulmonary disease
( C O P D ) ,a s t h m a ,c y s t i cf i b r o s i s ,l u n gc a n c e re t c .E B C s
mainly consist of water vapour but a small fraction con-
tains respiratory droplets derived from the airway lining
fluid [1,2]. This observation has created a growing inter-
est in the use of EBC as a new sampling method for the
screening of respiratory viruses infecting the upper air-
ways. At first, investigators suspected that turbulence of
the inhaled air was responsible for the aerosolisation of
the respiratory fluid. However, the effect of the turbu-
lent airflow is limited to the upper airways since the tur-
bulent airflow becomes laminar as it reaches the smaller
bronchial airways and alveoli. Recently, the bronchiole
fluid film burst model has been described [3]. This
model suggests that aerosols are produced during inha-
lation by the bursting of fluid bubbles present in the
bronchioles.
The aim of this study was to investigate whether the
EBC collection method was suited for the efficient con-
densation of aerosolised virus particles during normal
breathing and to explore the isolation of respiratory
viruses in the condensate. Therefore we screened the
EBC samples with virus specific PCR assays targeting 14
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(HRSV) A & B, Influenzavirus (Inf) A & B, Coronavirus
(CoV) NL63, E229 and OC43, Adenovirus (AdV),
Human Metapneumovirus (HMPV), Rhinovirus (RV)
and Parainfluenza virus (PIV) 1-4).
Methods
Sample collection
In this study, 102 EBCs were collected from otherwise
healthy volunteers showing respiratory or flu-like symp-
toms (defined in Table 1), using a commercially avail-
able condenser (RTube™, Respiratory Research Inc.,
Charlottesville, Virginia, USA). The patient was
instructed to breath orally at tidal volumes into a
mouthpiece attached to a condenser for 10 minutes. No
nose clips were used during collection and saliva con-
tamination was avoided by the presence of a one-way
valve and the T-shaped section of the mouthpiece.
In a first part of the study that started during the win-
ter and spring of 2008/2009, 70 EBC samples were col-
lected from patients who voluntary presented
themselves to our laboratory. The majority of these
volunteers were students that responded to the informa-
tion leaflet, distributed in the university buildings of the
Catholic University of Leuven. The samples were col-
lected with the aluminium cooler sleeve chilled at -80°C.
In the fall and first half of the winter of 2009/2010, 32
condensates were collected from patients who presented
themselves to their general practitioner. Due to practical
circumstances, the condensates were collected with the
cooler chilled at -20°C. For 13 out of 32 collections, the
RTube™ was connected by a custom made connecting-
piece to the ECoVent (Jaeger, Germany). This device
registers ventilatory parameters such as the exhaled
volume, breathing frequency and tidal volume. Addition-
ally, a NS was obtained in parallel with the condensate
collection from each patient.
All EBCs were immediately stored at -20°C. Nasal
swabs (NS) were refrigerated. After viral DNA and RNA
extraction, EBC samples and nasal swabs were stored at
-80°C. Three specimens were excluded from the study
due to incorrect condensate collection. A short ques-
tionnaire was used to document the date of birth, the
severity of respiratory complaints and to record the days
of symptomatic illness from all volunteers. This study
was approved by the Medical Ethics Committee of the
University Hospital of Leuven and informed consents
were received from all participants.
Viral RNA and DNA extraction
Viral DNA and RNA were isolated with the QIAamp
MinElute Virus kit (Qiagen, Westburg, The Netherlands)
according to the instruction manual. EBC extracts were
eluted in 60 μl elution buffer and NS extracts in 110 μl
elution buffer.
Virus detection and sequencing
The breath condensates were screened for 11 respiratory
RNA viruses (CoV NL63, E229 and OC43, RV, HMPV,
InfA&B and PIV1-4) [4-7] using a OneStep RT-PCR Kit
(Qiagen, Westburg, The Netherlands) in a 50 μl reaction
containing 10 μl of the extracted RNA, 0.6 μMo ff o r -
ward and reverse primers (Table 2), 1.5 μlO n eS t e p
Enzyme Mix, 10 μl 5 × One Step RT-PCR Buffer and
400 μM of each dNTP. For adenovirus screening, a
DNA PCR was carried out for which the amplification
reaction mix contained 0.5 μM forward primer (AdFW)
and reverse primer (AdRV), 0.4 mM dNTPs, 10 μlB u f -
fer C and 1 U Taq polymerase in a final volume of
50 μl. The PCR primers used were located in conserved
regions of the genomes of the respiratory pathogens
(Table 2). The reactions were carried out in a T3000
Thermocycler 48 (Westburg, Leusden, The Netherlands)
with an initial reverse transcription step for RNA viruses
at 50°C for 30 min, followed by PCR activation at 95°C
for 30 s, 45 cycles of amplification followed by a final
extension step for 10 min at 72°C. The DNA amplifica-
tion program was initiated with a denaturation step at
94°C for 3 min, followed by 45 cycles of 94°C for 30 s,
55°C for 30 s and a final extension step at 72°C for
1 min. The amplicons were subjected to a 6% polyacryla-
mide gel and visualised under UV light by staining with
ethidium bromide. PCR products were purified using the
Invitek MSB Spin PCRapace Kit and cycle sequenced in
forward and reverse direction using the ABI PRISM Big-
Dye Termination Cycle Sequencing Ready Reaction kit
(Applied Biosystems, Foster City, CA, USA). Sequence
analysis was performed with the ABI3130 Genetic Analy-
ser (Applied Biosystems, Foster City, CA, USA). Consen-
sus sequences were obtained using the SeqMan II
s o f t w a r e( D N A S T A R ,M a d i s o n ,W i s . ) .F o rs a m p l e sf r o m
Table 1 Clinical manifestations of subjects
Symptoms Serious Mild none
Fever 9 (8.8) 23 (22.5) 70 (68.6)
Headache 4 (3.9) 46 (45.1) 52 (51)
Shivering 7 (6.9) 27 (26.5) 68 (66.7)
Sneezing 43 (42.2) 41 (17.6) 18 (40.2)
Sore throat 38 (37.3) 34 (33.3) 30 (29.4)
Muscle ache 6 (5.9) 32 (31.4) 64 (62.7)
Watering eyes 7 (6.9) 27 (26.5) 68 (66.7)
Runny/stuffy nose 47 (46.1) 37 (36.3) 18 (17.6)
Coughing without chestpain 25 (24.5) 32 (31.4) 45 (44.1)
Coughing with chestpain 11 (10.8) 9 (8.8) 82 (80.4)
Figures represent the number of patients experiencing these clinical
manifestations. Figures between brackets are the percentages calculated to
total of 102 subjects.
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sufficient to verify the virus by BLAST search. In addition,
the VP4/VP2 partial region was amplified to confirm rhi-
novirus infection (data not shown). The nucleotide
sequences have been deposited to GenBank under acces-
sion numbers [HM74039 to HM747056].
HRSV was detected using a RT-PCR assay as previously
described [8,9]. In brief, a multiplex mix was prepared in a
final volume of 25 μl using 5 μl extracted RNA, 12.5 μlo f
Eurogentec One-Step Reverse Transcriptase qPCR Master
Mix containing ROX as a passive reference, 0.125 μl
Euroscript + RT & RNase inhibitor (Eurogentec, Seraing,
Belgium) 200 nM of HRSV-A and -B specific forward and
reverse primers and 100 nM of HRSV-A and -B MGB
probes. cRNA standards were constructed using the
MEGAshortscript T7 kit (Ambion, Austin, TX, USA) and
spectrophotometrically quantified.
The viral load of RV positive samples were quantified
by qRT-PCR as described in the manuscript published by
Lu and coworkers [10]. The Eurogentec One-Step
Reverse Transcriptase qPCR kit was used for preparation
of the master mix as described above. The primerset
Table 2 Primers for viral screening
Primer or probe Gene Position Sequence (5’® 3’) Reference
HRSV
RT-PCR primers
HRSV-AF F 669-695 ctgtgatagarttccaacaaaagaaca [8,9]
HRSV-AF F 718-745 agttacacctgcattaacactaaattcc [8,9]
HRSV-BN N 435-458 ggctccagaatataggcatgattc [8,9]
HRSV-BN N 480-508 tggttattacaagaagagcagctatacacagt [8,9]
MGB probes
HRSV-A TP F 697-715 cagactactagagattacc [8,9]
HRSV-B TP N 461-477 tatcatcccacagtctg [8,9]
INFLUENZA A
AM_FW155 M 151-174 catggaatggctaaagacaagacc [7]
AM_RV397 M 374-397 aagtgcaccagcagaataactgag [7]
INFLUENZA B
BHA_FW188 HA 188-209 agaccagagggaaactatgccc [7]
BHA_RV347 HA 324-347 ctgtcgtgcattataggaaagcac [7]
PARAINFLUENZA
PIV1FW HN 748-768 ccttaaattcagatatgtat [4]
PIV1RV HN 1206-1225 gataaataattattgatacg [4]
PIV2 FW HN 803-822 aacaatctgctgcagcattt [4]
PIV2 RV HN 1291-1310 argtcagacaatgggcaaat [4]
PIV3 FW HN 762-781 ctgtaaactcagacttggta [4]
PIV3 RV HN 1220-1239 tttaagcccttgtcaacaac [4]
PIV4 FW P 531-552 gaaagaggcttgggttacaca [21]
PIV4 RV P 1147-1168 gctcttatcacagtctccaaa [21]
HMPV
HMPV_N3F N 357-379 gagaagagctgggtagaa [6]
HMPV_N3R N 716-733 caaacaaactttctgct [6]
CORONA
PanCoV FW RdRp 13717-13739* acwcarhtvaayytnaartaygc [5]
PanCoV RV RdRp 13948-13967* tcrcayttdggrtartccca [5]
ADENO
AdFW Hexon 21-46 gccscartggkcwtacatgcacatc [22]
AdRV Hexon 301-322 cagcacsccicgratgtcaaa [22]
RV
RV_5UTR_FW 5’UTR 186-203 caagcacttctgtttccc [23]
RV_5UTR_RV 5’UTR 566-584 cacggacacccaaagtagt [23]
*Nucleotide positions for reference strain CoV NL63 (DQ445912).
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centration of 1 μM and 0.1 μM, respectively. cRNA stan-
dards were constructed based on the PCR product of
sample 1 using the MegaScript kit (Ambion, Austin, TX,
USA). Quantification was performed with a spectrophot-
ometer at 260 nm and converted to the molecule number
[11]. Tenfold serial dilutions, allowing detection in a
range of 8.6 × 10
6 to 8.6 × 10
2 RNA copies were used.
The RT-PCR assays were carried out on a ABI PRISM
7500 Sequence Detection System (Applied Biosystems,
Foster City, CA, USA). An initial reverse transcription
step was performed at 48°C for 30 min, followed by a
denaturation step at 95°C for 10 min. Finally, an amplifi-
cation step of 45 cycli at 95°C for 15 sec and 1 min at
60°C was completed.
Results
A total of 102 EBCs were collected from volunteers
showing a symptomatic respiratory infection. Seventy
were collected during the winter and spring of 2008/
2009 and 32 during the fall and first part of the winter
of 2009/2010. The first group of participants consisted
of 42 (60%) women and 28 (40%) men and a median
age of 32 years (range 19 - 83 years) was observed. The
second group existed of 18 (56.3%) women and 12
(37.5%) men, with a median age of 29 (range 9 - 46
years). Age and gender was missing for 2 participants of
the second group. In total, 52% of the participants were
between 20-30 years old. Only 6% were younger than 20
years old and 3% were older than 70 years. In totality,
80 patients (78.4%) were already feeling ill for 1 to 7
days at the day the sample was obtained. Seven volun-
teers (6.8%) were symptomatic for 8 to 14 days and 9
participants (8.8%) were already ill for more than 14
days at the day of sample collection. Data on the dura-
tion of symptoms was lacking for 6 patients. Almost all
volunteers experienced at least 2 symptoms except for
two patients (Table 1). Forty-seven (46.1%) volunteers
complained about a constant runny or stuffy nose, 43
(42.2%) had frequent sneezing events and 38 (37.3%)
participants had a serious sore throat (Table 1).
Viral screening
In a first part of the study, we collected 70 EBCs. Screen-
ing of the EBCs for 14 respiratory viruses (Table 2),
showed 5 RV (7.1%) positive samples (Table 3). In a
second part, we collected 32 EBCs from patients that
presented themselves to their general practitioner. Two
of these EBCs were positive for one of the 14 investigated
respiratory viruses, 1 for RV and 1 for InfB. To inspect
the detection rate of respiratory viruses in the conden-
sate, a NS was taken from this second group of volun-
teers for comparison. In 15 out of 32 NS (46.8%), one or
more viral pathogens were isolated. Viral screening of the
NS resulted in the detection of RV, InfA (subtype H1N1)
and HRSV-B. Quantification of the HRSV-B viral load
demonstrated for samples 72 and 101 viral titers of 8.0 ×
10
4 RNA copies/ml and 6.8 × 10
7 RNA copies/ml respec-
tively. The RV RT-PCR assay did not allow the quantifi-
cation of all samples that tested positive for RV by PCR
(Table 3). Presence of the same pathogen in both the
EBC and the NS was confirmed for only 1 sample: sample
71, which tested positive for RV in both the EBC and the
NS. For sample 81, RV was detected in the NS and analy-
sis of the EBC demonstrated an InfB infection.
Viral generation rate
For EBC samples that were collected in the fall and win-
ter of 2009/2010, measurements with the ECoVent in
Table 3 Viral screening of EBCs and NS
Patient EBC NS Viral load in NS RNA
copies per ml
(Mean Ct ± SD)
Days of illness at
time of collection
1 RV - ND 1
2 RV - ND 1
3 RV - ND 1
6 RV - ND 2
47 RV - ND 2
71 RV RV 8.8 × 10
4
(33.22 ± 0.34)
2
72 N HRSV-B
&R V
8.0 × 10
4
(40.74*)
1.8 × 10
5
(31.96 ± 0.06)
5
73 N RV 3.8 × 10
5
(30.86 ± 0.73)
4
74 N RV 1.5 × 10
6
(28.67 ± 0.29)
2
75 N RV ND 4
76 N RV ND 6
79 N InfA
(H1N1)
1
80 N RV 7.9 × 10
5
(29.66 ± 0.23)
1
81 InfB RV ND 14
83 N InfA
(H1N1)
2
87 N RV ND 1
89 N RV 2.0 × 10
7
(25.81 ± 0.11)
2
95 N RV 4.0 × 10
6
(28.53 ± 0.12)
2
96 N RV 6.0 × 10
6
(27.74 ± 0.82)
2
101 N HRSV-B 6.8 × 10
7
(29.18 ± 0.12)
3
RV = Rhinovirus, RSV-B = Respiratory Syncytial Virus B, InfA = Influenza A, InfB =
Influenza B, N = Negative, - = No sample available, ND = viral load could not be
determined.
SD = standard deviation * single detection.
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of the 32 collections. A mean volume of 763.5 litre air
(range 103.8 - 999.9) was exhaled during 5 min and
volunteers breathed with a mean breathing frequency of
20.8 (range 18.2 - 30.7) times per minute. Only 1 EBC
(Table 3, sample 81) was positive for InfB when using
the RTube™ in combination with the EcoVent. In the-
ory, the viral generation rate (number of viral RNA
copies exhaled per minute) can be predicted by quantifi-
cation of the exhaled viral load. Then, an estimation of
the RNA copies per litre exhaled air or per minute can
be calculated. Quantification of the exhaled InfB would
allow us to predict the generation rate for this virus.
Due to insufficient sample volume, we could not deter-
mine the number of RNA copies in the sample.
Discussion
Collection of exhaled breath condensates is a novel and
non-invasive method for obtaining samples of the upper
respiratory tract. The collection of EBC is easy to per-
form and can be conducted in a home environment.
This method is much more agreeable for the patient
when compared to the unpleasant and invasive collec-
tion of nasal swabs, BAL, aspirates, etc. This aspect ren-
ders the method very attractive for routine laboratory
diagnostics of viral infections. Most studies that perform
breath analyses for viral detection use modified face
masks, with a removable central region in electret or a
removable Teflon filter on which exhaled particles
impact [12-14]. With the RTube™ collection device,
aerosolized particles of the airway lining fluid are preci-
pitated into a condensate when the breath is cooled
which serves as an immediate starting point for molecu-
lar testing.
Until now, this is the study with the largest subset of
volunteers that investigated EBC as a specimen for the
detection of respiratory viruses. Previous studies
reported the inclusion of a limited subset of participants
and investigated the presence of a limited number of
viruses in the breath samples. The study performed by
Fabian and colleagues, included 12 volunteers [12].
Huynh and co-workers recruited 9 volunteers for
exhaled breath sampling [13]. In the study by Stelzer-
B r a i de ta l . ,5 0E B C sw e r ea n a l y s e d[ 1 4 ]a n dS t - G e o r g e
et al. report the participation of 12 adults [15]. These
studies have focused on the detection of InfA and -B,
PIV1-3, HRSV and HMPV, while we have screened the
samples for a panel of 14 commonly circulating respira-
tory viruses. Based on the analysis of 99 EBCs (3 EBCs
were excluded), our results support the exhalation of
RV and InfB in 7% of our samples. Since many of the
volunteers had already been experiencing symptoms for
1 to 7 days, we initially presumed that they were already
recovering from the infection and were no longer
exhaling the virus. For common cold infections it is sug-
gested that a person may already be infectious for 1 or 2
days before experiencing any symptoms. However, in a
second part of our study we started collecting EBCs in
parallel with nasal swabs from patients presenting them-
selves to their medical doctor, 1 to 3 days after onset of
symptoms. Only for 1 condensate the same pathogen
was detected in both the EBC and the NS. The detec-
tion rate for respiratory viral pathogens in the NS was
46.8% which is much higher than the 7% detection rate
in the EBCs. The low detection of virus positive conden-
sates can therefore not be attributed to the fact that
volunteers were no longer infectious. The discrepant
detection rate between samples may also be explained
by different severity of respiratory infection, since com-
parator samples were of different parts of the respiratory
tract. Patients that delivered a positive NS may have
possibly suffered from an upper airway infection
whereas EBC positive volunteers may have experienced
a more advanced, lower respiratory tract infection. How-
ever, the effect of nasal inhalation on EBC collection,
guiding formed particles in the upper respiratory tract
to the lower compartments, in stead of oral inhalation
was not investigated. Patients with positive EBC samples
were experiencing symptoms for maximum two days at
the time of collection. However, this was not different
for 7 patients with positive NS. Six patients that pro-
vided positive NS were experiencing symptoms for a
longer period at the time of collection (Table 3). In the
group of volunteers that provided an EBC negative or
EBC and NS negative sample, the manifestation of
symptoms were reported ranging from 1 day to more
than two weeks. When reported symptoms were com-
pared between EBC positive patients (7) and NS positive
patients (15), 27% and 33% in the positive NS group
experienced shivering and muscle pain whereas this
symptom was not indicated by any patient of the EBC
positive group. In all groups fever, headache, watering
eyes, stuffed nose, frequent sneezing, sore throat and
coughing were reported.
Volunteers were not diagnosed with other pathogens
before participation in the s t u d y .S i n c ew ed i dn o tt e s t
these samples for other than viral pathogens, we can not
exclude the possibility that some of the negative NS are
positive for bacteria or other pathogens causing respira-
tory illness. Recently, one study reported a detection
rate of 5% for influenza in EBC [15]. This is in the same
range of the detection rate that we report for respiratory
viruses in general. Other studies with a limited number
of patients, describe a markedly higher sensitivity of 33
to 36% [12-14] but the higher percentage may be due to
the low number of participants subjects were included
[12]. Remarkably, the studies reporting this higher
detection rate used collections masks, while the study
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masks consist of electret which trap viruses based on
permanently charged fibres [13]. In addition, the Teflon
filter has 2 μm pores which will retain all larger parti-
cles. Possibly, the lower detection rate can partly be
explained by the fact that the RTube™ is manufactured
in polypropylene and does not possess a virus attracting
and filtering feature like the aforementioned materials.
The qRT-PCR developed by Lu and coworkers for the
detection of RV, did not allow the assessment of the viral
load present in the EBC samples [10]. Also for 4 NS, the
viral titer remained undetermined, probably due to the
limited sensitivity of the assay. For diagnosis, more sensi-
tive methods might be necessary to detect respiratory
viruses present in EBC since it is unpredictable how
diluted the viral particles in the specimen are. Recently,
nested qRT-PCR assays have been developed to allow a
more sensitive detection of viruses in aerosols [16].
Also person-dependent factors, such as the number of
particles produced, the exhaled volume and the age of
the patient, have been suggested to play an important
role for exhalation of viral particles. The participants
that were recruited in the study of Fabian and cowor-
kers were 12 years of age and older [12]. For hospita-
lized children a much higher rate of virus positive
samples is reported [14]. In our study, the majority of
volunteers were between 20 and 30 years old. Only two
children less than 10 years and 3 elderly people (> 70
years) were included. One of the children tested positive
for InfA in the NS, but the infection was not confirmed
in the EBC.
For influenza, an exhaled generation rate of <3.2 to 20
influenza RNA copies per minute was predicted by
quantifying the virus aerosols that impacted on a remo-
vable Teflon filter of a collection mask [12]. We used
the RTube™ in combination with the ECoVent, that
allowed the registration of additional ventilation para-
meters such as breathing frequency and exhaled volume.
In this way, when the number of RNA copies in the
EBC is quantified, the amount of viral particles that are
exhaled per litre or per minute can be estimated. Unfor-
tunately, we were not able to predict a virus generation
rate for InfB since viral load remained undetermined.
Although an inventive, new and promising method,
EBC collected by the RTube™ does not appear to be
appropriate for diagnosis of respiratory infections. None-
theless, this method may provide an alternative for cur-
rent sample procurement for epidemiological studies of
circulating viruses. This technique also confirms the
observation that viruses are able to disseminate through
normal breathing, particularly RV.
In addition, EBC collection from patients during
respiratory infections may be further investigated for
biomarker patterns. In calves that were experimentally
infected with bovine RSV, an increase in leukotriene B4,
indicating oxidative stress, was observed. This increased
level was also associated with the development of bron-
chial hyperresponsiveness [17]. In humans, a transiently
elevated H2O2 level was observed during common cold
infection. This marker returned to baseline values when
volunteers recovered from infection. H2O2 has also been
recognized as an interesting marker in asthma, where it
is associated with chronic lower airway inflammation
[18]. In InfA infected volunteers, an increased CO level
was observed during upper respiratory infection. This
observation might imply that CO is an indicator of air-
way inflammation or represents one of the host defence
mechanisms against viral infection [19]. Therefore, a
better identification of the biomarker signature in con-
densates of individuals experiencing a viral infection
might imply interesting findings towards the identifica-
tion of markers reflecting inflammation or antiviral pro-
tection. This may contribute to the biomarker profiles
established for diseases like asthma and COPD, for
which viral infections are suggested to trigger or exacer-
bate symptoms [20].
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